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UNITAID can address 
HCV/HIV co-infection
In the ﬁ  rst days of March, the govern-
ing body of UNITAID, the organisation 
ﬁ  nanced mainly through a levy on air 
tickets, will decide on a new 4-year 
strategy. A 5-year evaluation
1 praised 
UNITAID’s success  ful “market impact” 
model for improving access to HIV, 
tuberculosis, and malaria products 
through lower  ing prices, improving 
supply, or introducing new products. We 
believe UNITAID’s new strategy should 
also include tackling a prevalent and 
serious, but curable, HIV co-morbidity: 
hepatitis C virus (HCV) infection.
Worldwide, an estimated 4–5 million 
people are HCV/HIV co-infected.
2 HCV 
is a leading cause of death in people 
with HIV in western settings and causes 
substantial morbidity and mortality in 
the many co-infected people in low-
income and middle-income countries. 
HIV acceler  ates HCV progression, and 
HCV co-infection is associated with 
higher rates of all-cause, liver-related, 
and AIDS-related death.
3,4
Access to treatment with pegylated 
interferon alfa and ribavirin is extremely 
limited in low-resource settings owing 
to the regimen’s complexity, duration 
(48 weeks), and cost (up to US$30 000). 
Outcomes in low-income and middle-
income countries are similar to those 
reported in high-income countries; 
sustained virological response for 
co-infection can be as high as 60% 
depending on genotype.
5 
Fortunately, the HCV drug pipeline 
is extremely promising, thanks to 
proﬁ   table markets in high-income 
countries. New, more tolerable, all-oral 
regimens are showing remarkable cure 
rates in clinical trials. These shorter 
regimens might no longer require 
genotyping or complex monitoring. 
Simpler, better treatment is key for 
resource poor settings—but new drugs 
must become available and aﬀ  ordable.
UNITAID is already committed to HIV 
co-morbidities; its expertise and track 
record in lowering antiretroviral prices 
for developing countries sh ould now be 
applied to HCV. UNITAID can guarantee 
and pool initial drug demand, negotiate 
price reductions, and facilitate generic 
competition as appropriate and 
feasible, support quality assurance 
through WHO’s Pre-Qualiﬁ  cation 
Programme, introduce simpler 
diagnostics when becoming available, 
and generate demand forecasts, as 
countries start increasing access to HCV 
treatment. UNITAID’s unique role is to 
lower prices; organisations such as the 
Global Fund to ﬁ  ght AIDS, Tuberculosis 
and Malaria and the US President’s 
Emergency Plan for AIDS Relief should 
help in scaling up treatment.
Inclusion of HCV/HIV co-infection in 
UNITAID’s new strategy would have 
a dramatic eﬀ  ect on health and keep 
UNITAID at the forefront of market 
impact interventions.
We declare that we have no conﬂ  icts of interest.
*Tido von Schoen-Angerer, 
Jennifer Cohn, Tracy Swan, Peter Piot 
tido.von.schoenangerer@gmail.com
Médecins Sans Frontières, Geneva, Switzerland 
(TvSA, JC); Department of Pediatrics, HFR, Fribourg, 
Switzerland (TvSA); Treatment Action Group, New 
York, NY, USA (TS); and London School of Hygiene 
and Tropical Medicine, London, UK (PP)
1  ITAD. UNITAID 5 year evaluation. http://www.
unitaid.eu/images/Five-year-evaluation/5YE%20
Exec%20Summary-UNITAID%202012-12-
03%2016h00.pdf (accessed Feb 12, 2013).
2  Alter MJ. Epidemiology of viral hepatitis and HIV 
co-infection. J Hepatol 2006; 44 (suppl 1): S6–9.
3  van der Helm J, Geskus R, Sabin C, et al, for the 
CASCADE collaboration in EuroCoord. Eﬀ  ect of 
HCV infection on cause-speciﬁ  c mortality 
following HIV seroconversion before and after 
1997. Gastroenterology 2012; published online 
Dec 22. http://dx.doi.org/ 10.1053/j.
gastro.2012.12.026.
4  Hernando V, Perez-Cachafeiro S, Lewden C, 
et al. All-cause and liver-related mortality in 
HIV positive subjects compared to the general 
population: diﬀ  erences by HCV co-infection. 
J Hepatol 2012; 57: 743–51.
5  Davies A, Singh KP, Shubber Z, duCros P, et al. 
Treatment outcomes of treatment-naïve 
hepatitis C patients co-infected with HIV: 
a systematic review and meta-analysis of 
observational cohorts. PLoS One 2013; 8: e55373.
Lozano R, Naghavi M, Foreman K, et al. Global 
and regional mortality from 235 causes of death 
for 20 age groups in 1990 and 2010: a 
systematic analysis for the Global Burden of 
Disease Study 2010. Lancet 2012; 
380: 2095–128—In this Article (Dec 15/22/29), 
Mohammad A AlMazroa and Ziad A Memish 
have been added to the author list and the 
aﬃ   liation details have been updated. These 
changes have been made to the online version 
as of Feb 22, 2013.
Salomon JA, Vos T, Hogan DR, et al. Common 
values in assessing health outcomes from disease 
and injury: disability weights measurement study 
for the Global Burden of Disease Study 2010. 
Lancet 2012; 380: 2129–43—In this Article 
(Dec 15/22/29), Jost B Jonas has been added to 
the author list and the aﬃ   liation details have 
been updated. These changes have been made 
to the online version as of Feb 22, 2013.
Salomon JA, Wang H, Freeman MK, et al. Healthy 
life expectancy for 187 countries, 1990–2010: a 
systematic analysis for the Global Burden of 
Disease Study 2010. Lancet 2012; 
380: 2144–62—In this Article (Dec 15/22/29), a 
coding error led to the wrong values being used 
for life-years lived at ages 80 years and older. 
This error has been corrected, leading to 
changes to the data in the Findings section of 
the Summary, the Results and Discussion 
sections in the main text, table 1, the healthy 
life expectancy data in table 2, some of the data 
in tables 4 and 5, to ﬁ  gures 1, 3, 4, and 5, and to 
the appendix. These corrections have been 
made to the online version as of Feb 22, 2013.
Vos T, Flaxman AD, Naghavi M, et al. Years lived 
with disability (YLDs) for 1160 sequelae of 
289 diseases and injuries 1990–2010: a systematic 
analysis for the Global Burden of Disease Study 
2010. Lancet 2012; 380: 2163–96—In this 
Article (Dec 15/22/29), Mohammad A AlMazroa 
and Ziad A Memish have been added to the 
author list and the aﬃ   liation details have been 
updated. These changes have been made to the 
online version as of Feb 22, 2013.
Murray CJL, Vos T, Lozano R, et al. Disability-
adjusted life years (DALYs) for 291 diseases and 
injuries in 21 regions, 1990–2010: a systematic 
analysis for the Global Burden of Disease Study 
2010. Lancet 2012; 380: 2197–223—In this 
Article (Dec 15/22/29), Mohammad A 
AlMazroa and Ziad A Memish have been added 
to the author list and the aﬃ   liation details 
have been updated. These changes have been 
made to the online version as of Feb 22, 2013.
Lim SS, Vos T, Flaxman AD, et al. A comparative 
risk assessment of burden of disease and injury 
attributable to 67 risk factors and risk factor 
clusters in 21 regions, 1990–2010: a systematic 
analysis for the Global Burden of Disease Study 
2010. Lancet 2012; 380: 2224–60—In this 
Article (Dec 15/22/29), Mohammad A AlMazroa 
and Ziad A Memish have been added to the 
author list and the aﬃ   liation details have been 
updated. These changes have been made to 
the online version as of Feb 22, 2013.
T
e
k
 
I
m
a
g
e
/
S
c
i
e
n
c
e
 
P
h
o
t
o
 
L
i
b
r
a
r
y
 